Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cephalon, Inc. (NasdaqNM:CEPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug  7Conference call: Cephalon Earnings (Q2 2001)
Aug  7Earnings Announcement
Location
145 Brandywine Parkway
West Chester, PA 19380
Phone: (610) 344-0200
Fax: (610) 344-0065
Email: smenta@cephalon.com
Employees (last reported count): 513
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 44%
·Over the last 6 months:
 · 14 insider sells; 166.0K shares
  (0.7% of insider shares)
·Institutional: 88% (156% of float)
(444 institutions)
·Net Inst. Buying: 4.10M shares (+8.53%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cephalon, Inc. is an international biopharmaceutical company focused on the discovery, development and marketing of products to treat sleep disorders, neurological disorders, cancer and pain. In the United States, the Company markets three products, Provigil (modafinil) Tablets [C-IV] for treating excessive daytime sleepiness associated with narcolepsy, Actiq (oral transmucosal fentanyl citrate) [C-II] for the management of cancer pain in opioid tolerant patients, and Gabitril (tiagabine hydrochloride) for the treatment of partial seizures associated with epilepsy. In the United Kingdom, the Company markets Provigil and five other products, including Tegretol (carbamazepine), a treatment for epilepsy, and Ritalin (methylphenidate), a treatment for attention deficit hyperactivity disorder (ADHD). The Company also markets other products in France, Germany, Austria and Switzerland.
More from Market Guide: Expanded Business Description

Financial Summary
CEPH is a biopharmaceutical company that develops and markets products to treat neurological and sleep disorders, cancer and pain. For the six months ended 6/30/01, revenues totaled $103.3 million, up from $43 million. Net loss applicable to Common and before accounting change and extraordinary item fell 30% to $21.1 million. Revenues reflect increased sales of Provigil, Actiq and Gabitril. Lower loss was partially offset by higher selling and marketing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Frank Baldino, Jr., Ph.D., 47
Chairman, Pres, CEO
$3.6M$4.1M
J. Kevin Buchi, 45
Sr. VP - Fin. and CFO
913K198K
John Osborn, 43
Sr. VP, Gen. Counsel and Sec.
--  --  
Carl Savini, 51
Sr. VP, HR
--  --  
Paul Blake, 53
Sr. VP, Clinical Research and Regulatory Affairs
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CEPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$36.375
Recent Price$59.22 
52-Week High
on 3-July-2001
$73.92 
Beta0.91 
Daily Volume (3-month avg)831.0K
Daily Volume (10-day avg)622.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+12.8%
52-Week Change
relative to S&P500
+51.3%
Share-Related Items
Market Capitalization$2.97B
Shares Outstanding50.1M
Float28.1M
Dividends & Splits
Annual Dividend (indicated)$0.90 
Dividend Yield1.52%
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.44 
Earnings (ttm)-$2.50 
Earnings (mrq)-$0.20 
Sales (ttm)$4.24 
Cash (mrq)$8.43 
Valuation Ratios
Price/Book (mrq)17.20 
Price/EarningsN/A 
Price/Sales (ttm)13.97 
Income Statements
Sales (ttm)$177.1M
EBITDA (ttm)-$87.7M
Income available to common (ttm)-$103.0M
Profitability
Profit Margin (ttm)-52.5%
Operating Margin (ttm)-53.5%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-27.66%
Return on Equity (ttm)-63.02%
Financial Strength
Current Ratio (mrq)10.74 
Debt/Equity (mrq)2.61 
Total Cash (mrq)$420.8M
Short Interest
As of 8-Aug-2001
Shares Short4.42M
Percent of Float15.7%
Shares Short
(Prior Month)
4.65M
Short Ratio5.03 
Daily Volume878.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.